- Disorders associated with neutropenia (ANC < 1.5 x 10E9/L) or thrombocytopenia (platelet count < 50 x 10E9/L) in the 12 months preceding the initiation of the study medication. Exception: for patients whose neutropenia was attributed by the treating physician to episodes of infection or to drugs associated with a decline in the neutrophil count and in whom the ANC has fully recovered at the screening visit;